NAR Cancer

Scope & Guideline

Innovating diagnostics and treatments for tomorrow's healthcare.

Introduction

Welcome to the NAR Cancer information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of NAR Cancer, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN2632-8674
PublisherOXFORD UNIV PRESS
Support Open AccessYes
CountryUnited Kingdom
TypeJournal
Convergefrom 2019 to 2024
AbbreviationNAR CANCER / NAR Cancer
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND

Aims and Scopes

NAR Cancer is dedicated to advancing our understanding of cancer biology through innovative research that explores the molecular mechanisms underpinning cancer development and progression. The journal aims to provide a platform for high-quality research that contributes to the fields of genomics, molecular biology, and therapeutic strategies in oncology.
  1. Molecular Mechanisms of Cancer:
    Research focusing on the molecular and cellular processes that drive cancer, including DNA repair mechanisms, transcriptional regulation, and RNA modifications.
  2. Cancer Genomics and Epigenomics:
    In-depth studies on the genomic alterations associated with various cancers, including next-generation sequencing technologies and analyses of epigenetic changes.
  3. Therapeutic Strategies and Resistance Mechanisms:
    Investigations into novel therapeutic approaches and the mechanisms of drug resistance, particularly in relation to targeted therapies and immunotherapies.
  4. Tumor Microenvironment and Immune Interactions:
    Exploration of the interactions between tumor cells and their microenvironment, including immune evasion and the role of non-coding RNAs.
  5. Data Integration and Computational Biology:
    Utilization of bioinformatics and computational methods to integrate multi-omics data for better insights into cancer biology and treatment outcomes.
Recent publications in NAR Cancer indicate evolving research trends that reflect the dynamic nature of cancer research. Emerging themes highlight innovative approaches and technologies that are shaping the future of oncology.
  1. RNA Modifications and Translation Dynamics:
    An increasing number of studies focus on the role of RNA modifications, such as m6A methylation, and their implications for translation control and cancer progression.
  2. Extrachromosomal DNA and Genomic Instability:
    Research into extrachromosomal DNA and its relationship with genomic instability is gaining traction, revealing new insights into cancer evolution and therapy resistance.
  3. CRISPR and Gene Editing Technologies:
    The application of CRISPR and other gene editing technologies is trending, with studies exploring their potential for targeted therapies and functional genomics in cancer.
  4. Immune Microenvironment and Tumor Immunology:
    There is a notable increase in research addressing the tumor immune microenvironment, emphasizing the importance of immune interactions in cancer therapy and patient prognosis.
  5. Integration of Multi-Omics Data:
    The trend towards integrating multi-omics data (genomics, transcriptomics, proteomics) is emerging, facilitating a comprehensive understanding of cancer biology and therapeutic responses.

Declining or Waning

While NAR Cancer continues to thrive in several research areas, certain themes have seen a decline in prominence over the recent years. These waning scopes may reflect shifts in research priorities or advancements that have rendered some topics less central to current discussions.
  1. Traditional Chemotherapy Mechanisms:
    Research focusing on classical chemotherapy mechanisms has decreased as attention shifts towards precision medicine and targeted therapies that better address the complexities of cancer.
  2. Basic Histology and Morphological Studies:
    Studies primarily centered on histological and morphological aspects of cancer are becoming less common, as molecular and genetic approaches gain precedence in understanding cancer biology.
  3. Single-Agent Drug Studies:
    The focus on single-agent drug efficacy studies is diminishing, with a greater emphasis now placed on combination therapies and multi-target approaches that reflect the complexity of cancer treatment.

Similar Journals

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS

Transforming Our Understanding of Mutagenesis
Publisher: ELSEVIERISSN: 1386-1964Frequency: 12 issues/year

MUTATION RESEARCH - FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS is a premier peer-reviewed journal published by Elsevier, dedicated to advancing the understanding of mutagenesis and its broader implications in genetics, health, and molecular biology. With an impressive converged publication history from 1964 to 2024, this journal provides a vital platform for the dissemination of high-quality research findings, contributing significantly to the field's knowledge base. Indexed in Scopus, it holds a Category Quartile ranking of Q3 in Genetics and Q2 in Health, Toxicology, and Mutagenesis, further underscoring its relevance and stature. Access options are available, catering to a diverse audience of researchers, professionals, and students eager to stay informed on the latest developments in mutagenesis research. By bridging experimental studies and theoretical frameworks, the journal plays a crucial role in exploring the fundamental mechanisms underlying genetic mutations and their effects on human health and the environment.

ONCOGENE

Illuminating the Pathways of Molecular Oncology
Publisher: SPRINGERNATUREISSN: 0950-9232Frequency: 50 issues/year

ONCOGENE is a premier peer-reviewed journal published by SpringerNature, serving as a crucial platform for innovative research within the fields of Cancer Research, Genetics, and Molecular Biology. With an impressive Impact Factor and a distinguished Q1 ranking across major categories, ONCOGENE publishes cutting-edge studies aimed at unraveling the complexities of cancer biology and genetic mechanisms. The journal has been a vital resource for the academic community since its inception in 1987, and it continues to foster rigorous scientific discussions and collaborations. Researchers, professionals, and students can access a wealth of critical insights and advances in cancer genomics and therapeutic approaches, cementing ONCOGENE’s role as a leading voice in the landscape of biomedical research. For comprehensive academic research, ONCOGENE remains an indispensable source of knowledge with contributions that significantly impact the evolution of cancer research and treatment strategies.

Oncologie

Pioneering insights in the fight against cancer.
Publisher: WALTER DE GRUYTER GMBHISSN: 1292-3818Frequency: 6 issues/year

Oncologie is a distinguished academic journal published by WALTER DE GRUYTER GMBH, focusing on the dynamic and vital field of oncology. Established in 1999 and continuously published until 2024, this journal provides a platform for high-quality research and advancements in cancer treatment, prevention, and diagnosis. With an ISSN of 1292-3818 and an E-ISSN of 1765-2839, it is indexed in various databases, contributing to its growing visibility. Although categorized in the Q3 quartile for oncology research as of 2023, Oncologie offers essential insights and fosters scholarly dialogue among researchers, professionals, and students interested in oncology. Its unique contributions aim to bridge the gap between theoretical frameworks and clinical applications, making it a valuable resource for those seeking to advance their knowledge and expertise in cancer research.

Molecular & Cellular Oncology

Connecting researchers to the forefront of oncology.
Publisher: TAYLOR & FRANCIS INCISSN: Frequency: 6 issues/year

Molecular & Cellular Oncology, published by Taylor & Francis Inc, is a vital academic journal dedicated to the exploration of cancer biology through the lens of molecular and cellular mechanisms. Since its inception in 2014, the journal has played a crucial role in disseminating innovative research findings that address the fundamental aspects of cancer research and molecular medicine. With its current ranking in Scopus placing it in the Q3 quartile for both Cancer Research and Molecular Medicine, the journal provides a platform for groundbreaking studies that push the boundaries of our understanding of oncogenesis and therapeutic interventions. Although the journal operates under a subscription model, its dedication to high-quality peer-reviewed research makes it an essential resource for researchers, professionals, and students aiming to contribute to or stay updated in the rapidly evolving field of oncology. As we approach the culmination of its converged years in 2024, Molecular & Cellular Oncology aims to continue fostering collaborations and insights that advance cancer research on a global scale.

CURRENT CANCER DRUG TARGETS

Unveiling novel therapeutic avenues in the fight against cancer.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1568-0096Frequency: 11 issues/year

CURRENT CANCER DRUG TARGETS is a prominent academic journal published by Bentham Science Publishers Ltd, focusing on the critical intersection of cancer research and innovative drug development. Since its inception in 2001, this journal has offered a platform for the dissemination of cutting-edge research aimed at advancing targeted cancer therapies, contributing significantly to the fields of Cancer Research, Drug Discovery, Oncology, and Pharmacology. With a respectable impact factor and consistent ranking in its respective categories, including Q2 in Drug Discovery and Pharmacology, it positions itself as an invaluable resource for researchers, clinicians, and students alike. CURRENT CANCER DRUG TARGETS is dedicated to enhancing our understanding of novel therapeutic targets and methods, thereby fostering a collaborative environment for knowledge exchange in the ever-evolving landscape of cancer treatment.

JOURNAL OF GENE MEDICINE

Exploring the Future of Genetic Innovation
Publisher: WILEYISSN: 1099-498XFrequency: 12 issues/year

The Journal of Gene Medicine, published by Wiley, stands as a pivotal resource in the field of gene therapy and molecular medicine, with a rich history of dissemination of impactful research since its inception in 1998. With an ISSN of 1099-498X and an E-ISSN of 1521-2254, this esteemed journal plays a crucial role in advancing our understanding of genetics and drug discovery, reflected in its impressive 2023 Scopus rankings where it holds a Q2 classification in Drug Discovery and Q3 in several genetics-related categories. The journal aims to facilitate the exchange of high-quality research findings that bridge the gap between laboratory and clinical applications, making it an essential platform for researchers, academics, and healthcare professionals committed to the forefront of genetic innovation. Although it does not currently offer open access options, its reputation for rigorous peer review ensures that all published work meets the highest academic standards, providing a reliable reference for scientific inquiry in the United States and beyond. As the field rapidly evolves, the Journal of Gene Medicine remains at the helm, guiding future discoveries with its influential publications and comprehensive insights.

Oncogenesis

Leading the charge in oncogenesis research and education.
Publisher: SPRINGERNATUREISSN: 2157-9024Frequency: 1 issue/year

Oncogenesis is a prestigious open access journal, published by SpringerNature, dedicated to advancing our understanding of cancer biology and molecular mechanisms of oncogenesis. Since its inception in 2012, this journal has quickly established itself as a leading platform for innovative research, being ranked in the Q1 quartile in both Cancer Research and Molecular Biology categories for 2023. With an admirable impact factor that reflects its exceptional quality, Oncogenesis is indexed in Scopus, holding notable rankings in both Molecular Biology and Cancer Research, placing in the 87th and 83rd percentile respectively. The journal not only facilitates the dissemination of groundbreaking research but also encourages collaboration among scientists and healthcare professionals across the globe. By offering open access to its articles, Oncogenesis ensures that vital findings reach a diverse audience, fostering a deeper dialogue and understanding in the fight against cancer. Based in the United States but with a global reach, the journal remains committed to publishing high-impact studies that contribute to the advancement of knowledge in the realms of oncology, biochemistry, and genetics.

GENE

Connecting Researchers to Groundbreaking Genetic Discoveries
Publisher: ELSEVIERISSN: 0378-1119Frequency: 48 issues/year

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.

CELL RESEARCH

Exploring Innovations in Molecular Biology
Publisher: SPRINGERNATUREISSN: 1001-0602Frequency: 12 issues/year

CELL RESEARCH is a premier peer-reviewed journal dedicated to advancing the field of cell biology and molecular biology, published by SpringerNature. With an impressive impact factor and consistently ranking in the Q1 quartile for both cell biology and molecular biology, this journal serves as a pivotal resource for researchers, professionals, and students seeking to explore the latest discoveries and advancements in cellular mechanisms and their implications for health and disease. Since its inception in 1996, CELL RESEARCH has cultivated a distinguished reputation, currently boasting ranks in the top percentile of Scopus categories, reaffirming its influence and relevance to the scientific community. Although it is not an Open Access journal, its rigorous selection process ensures the publication of high-quality articles that contribute significantly to our understanding of life sciences. For those deeply engaged in the realms of biochemistry, genetics, and molecular biology, CELL RESEARCH is an essential conduit of innovative research and critical insights.

CELLULAR & MOLECULAR BIOLOGY LETTERS

Illuminating Cellular Processes Through Open Access Research
Publisher: BMCISSN: 1425-8153Frequency: 1 issue/year

CELLULAR & MOLECULAR BIOLOGY LETTERS, published by BMC, is a premier open-access journal dedicated to disseminating high-quality research in the fields of Biochemistry, Cell Biology, and Molecular Biology. Established in 1996, the journal has emerged as a leader in its domain, boasting an impressive Q1 ranking across three critical categories as of 2023, reflecting its significant impact within the scientific community. With an ISSN of 1425-8153 and an E-ISSN of 1689-1392, it offers accessible research findings to a global audience, having been open access since 2013. Situated in the United Kingdom, at CAMPUS, 4 CRINAN ST, LONDON N1 9XW, the journal continues to serve as a vital resource for researchers, professionals, and students, contributing to advancements in the understanding of cellular and molecular processes. By providing a platform for original research, reviews, and short communications, CELLULAR & MOLECULAR BIOLOGY LETTERS plays a crucial role in fostering dialogue and collaboration within the scientific community.